0000905148-24-001109.txt : 20240405 0000905148-24-001109.hdr.sgml : 20240405 20240405174715 ACCESSION NUMBER: 0000905148-24-001109 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240403 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Amado Rafael CENTRAL INDEX KEY: 0001662119 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 24827646 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 form4.xml X0508 4 2024-04-03 0001704292 Zai Lab Ltd ZLAB 0001662119 Amado Rafael C/O ZAI LAB LIMITED 314 MAIN STREET, 4TH FLOOR, SUITE 100 CAMBRIDGE MA 02142 true See Remarks false American Depositary Shares 2024-04-03 4 M 0 5391 15.9 A 25484 D American Depositary Shares 2024-04-04 4 S 0 1952 15.673 D 23532 D Restricted Share Units 2024-04-03 4 M 0 5391 0 D American Depositary Shares 5391 16173 D Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. ADSs acquired upon vesting of Restricted Share Units ("RSUs"). These ADSs were sold automatically to cover taxes upon vesting of RSUs. Each RSU represents a contingent right to receive one ADS. The RSUs vest in equal annual installments over four years beginning on 04/03/2024, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. President, Head of Global Oncology Research and Development /s/ Bruce Blefeld, Attorney-in-Fact 2024-04-05